Genentech Avastin Line At Vacaville Facility Gains FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Product produced at the Vacaville, Calif. site will start shipping by September, Genentech says. The South San Francisco facility will continue to manufacture Avastin.
You may also be interested in...
Wyeth Enters Manufacturing Agreement for Genentech's Herceptin
Bulk drug substance for Herceptin will be manufactured at Wyeth's Andover, Mass. facility. The companies should be familiar with this type of arrangement since Genentech signed a deal in 2002 to manufacture Wyeth/Amgen's Enbrel.
Wyeth Enters Manufacturing Agreement for Genentech's Herceptin
Bulk drug substance for Herceptin will be manufactured at Wyeth's Andover, Mass. facility. The companies should be familiar with this type of arrangement since Genentech signed a deal in 2002 to manufacture Wyeth/Amgen's Enbrel.
Avastin Labeling Will Reflect New Data On Thromboembolic Events
Genentech's "Dear Doctor" letter cites evidence of an "increased risk of serious arterial thromboembolic events" related to use of the oncologic. A revised package insert containing more detailed information on arterial thromboembolic events across five studies is in development, the company says.